Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas

NCT01721577 is registered in ClinicalTrials.gov with Rush University Medical Center as lead sponsor.

NCT NCT01721577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01721577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Lead sponsor
Rush University Medical Center
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2012
Completion date
December 31, 2015
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma